This Implementation Kit (I-Kit), developed by the Health Communication Capacity Collaborative (HC3), helps national and local stakeholders to design country-specific social and behavioural change communication (SBCC) campaigns that address the threat posed by substandard, spurious, falsified and fal...sely labelled (SSFFC) malaria medicines. These poor-quality medicines endanger lives by failing to treat malaria effectively, undermine health systems, and contribute to drug resistance.
The I-Kit provides practical guidance and resources in six sections, including global examples, campaign design elements, media engagement strategies and tools for knowledge sharing. It is intended for health promotion officers, drug regulators, communication specialists and global health partners. Drawing heavily on experiences in Nigeria, the I-Kit promotes evidence-based, context-sensitive SBCC interventions to safeguard communities against SSFFC malaria medicines and enhance treatment outcomes.
more
The WHO guidelines for malaria bring together the Organization’s most up-to-date recommendations for malaria in one user-friendly and easy-to-navigate online platform.
The WHO guidelines for malaria bring together the Organization’s most up-to-date recommendations for malaria in one user-frie...ndly and easy-to-navigate online platform. The Guidelines supersedes 2 previous WHO publications: the Guidelines for the treatment of malaria, third edition and the Guidelines for malaria vector control. Recommendations on malaria will continue to be reviewed and, where appropriate, updated based on the latest available evidence. Any updated recommendations will always display the date of the most recent revision in the MAGICapp platform. With each update, a new PDF version of the consolidated guidelines will also be available for download on the WHO website.
This version of the Guidelines includes an updated recommendation for malaria vaccines, new recommendations on the use of near-patients qualitative and semiquantitative G6PD tests to guide anti-relapse treatment of P. vivax and P. ovale, updated recommendations on primaquine and the recommendation on the use of tafenoquine. It replaces the versions published on 16 February 2021, 13 July 2021, 18 February 2022, 31 March 2022, 3 June 2022, 25 November 2022, 14 March 2023 and 16 October 2023.
more
La lutte antivectorielle est un élément essentiel des stratégies de prévention, de contrôle et d'élimination du paludisme, car elle peut s'avérer très efficace pour assurer la protection des personnes et/ou réduire la transmission de la maladie.
Reprogramming examples for GC7. This document supports the introduction of climate change-related interventions
into programs to reduce transmission of malaria and protect vulnerable populations.
Thematic brief. This brief highlights the link between climate change and VBDs in Asia Pacific. Using malaria to tell the narrative, it lists key actions that policymakers and the public health community can consider in addressing the impact of a changing climate on health. The brief also includes ...a list of resources that countries can benefit from in planning their response.
more
Le Plan Stratégique National de Lutte contre le Paludisme 2023–2026 du Togo définit les grandes orientations pour réduire de 65 % l’incidence et la mortalité liées au paludisme d’ici 2026, en comparaison avec les niveaux de 2022. Élaboré par le Programme National de Lutte contre le Pa...ludisme (PNLP), il s’inscrit pleinement dans les objectifs mondiaux fixés par l’Organisation mondiale de la Santé pour parvenir à l’élimination du paludisme d’ici 2030. Ce plan repose sur quatre axes stratégiques : la prévention à travers l’utilisation des moustiquaires imprégnées, la chimio-prévention et la lutte antivectorielle ; la prise en charge efficace des cas grâce au diagnostic rapide et au traitement par ACT ; le renforcement du système de santé et la gestion du programme ; ainsi que la surveillance, le suivi et l’évaluation des interventions. Une attention particulière est accordée à la digitalisation des outils, à l’amélioration de la qualité des données, à l’implication des communautés locales et à la réduction des inégalités régionales dans l’accès aux services. Intégrant les partenaires techniques et financiers, le secteur privé et les acteurs communautaires, ce document constitue une véritable feuille de route nationale pour coordonner et intensifier la lutte contre le paludisme sur la période 2023–2026.
more
Le Plan stratégique national de plaidoyer en matière de lutte contre le paludisme (PSNPP) 2018-2023 servira à harmoniser la programmation des actions de plaidoyer et à garantir que les interventions de plaidoyer sont alignées sur les priorités du Plan stratégique national de lutte contre le p...aludisme (PSNP) 2016-2020. Il va guider
les professionnels du changement social et comportemental et de la communication en santé, et les autres parties prenantes concernées à concevoir, mettre en œuvre, surveiller et évaluer les interventions de plaidoyer pour s’assurer qu’elles sont compatibles avec les politiques nationales et internationales actuelles. Ce guide, développé à travers un processus stratégique qui prend en compte les principes d’une stratégie efficace, est localisé, ciblé, prouvé, collaboratif, influent, redevable et pérenne.
more
Le Plan Stratégique National de Lutte contre le Paludisme 2023–2027 de la Guinée vise à réduire de 80 % l’incidence et la mortalité liées au paludisme d’ici 2027, en s’appuyant sur les leçons des années précédentes. Il prévoit des actions renforcées de prévention (moustiquaire...s, lutte antivectorielle, chimio-prévention saisonnière, prévention chez les femmes enceintes et les enfants), une amélioration de la prise en charge des cas à tous les niveaux (public, privé, communautaire), ainsi qu’un renforcement de la gestion, des ressources, de la gouvernance, de la communication et de l’évaluation. L’objectif final est de guider le pays vers la pré-élimination du paludisme, en assurant l’accès universel à des soins de qualité et en mobilisant tous les acteurs nationaux et internationaux.
more
Le Plan Stratégique National de Lutte contre le Paludisme au Sénégal 2021–2025 a pour objectif de réduire l’incidence et la mortalité liées au paludisme d’au moins 75 % par rapport à 2019 et d’interrompre la transmission locale dans au moins 80 % des districts éligibles. Il repos...e sur une approche multisectorielle combinant prévention (moustiquaires, pulvérisation, chimioprévention), diagnostic, traitement, surveillance, gestion des stocks et communication pour le changement de comportement. Le plan vise aussi à renforcer la gouvernance, l’équité, la recherche et la mobilisation des ressources, en s’appuyant sur les partenariats locaux, privés et internationaux pour atteindre l’objectif d’un Sénégal sans paludisme à l’horizon 2030.
more
La Stratégie Nationale de Plaidoyer et de Mobilisation des Ressources en faveur de la Lutte contre le Paludisme 2024–2028 en République Démocratique du Congo vise à renforcer l’engagement politique, mobiliser des financements domestiques et internationaux et impliquer tous les secteurs (publ...ic, privé, société civile) pour réduire la mortalité liée au paludisme de 70 % et l’incidence de 50 % d’ici 2028.
Le document propose des actions concrètes : plaidoyer auprès des décideurs pour des budgets accrus, exonération des intrants antipaludiques, introduction du vaccin R21/Matrix-M, création de partenariats public-privé, implication des leaders communautaires et campagnes de sensibilisation via les médias. Il s’aligne sur la stratégie mondiale de l’OMS et promeut une approche multisectorielle, coordonnée par le Programme National de Lutte contre le Paludisme avec l’appui de partenaires comme l’USAID et Breakthrough ACTION.
more
This guidance covers different options for banning or phasing out a pesticide and suggests related risk reduction measures to be taken during the phase-out period. A key focus of this guidance is how to take action to manage, prevent, minimize, and communicate about identified risks during the imple...mentation of a phase-out strategy. It contains a description of legal aspects to consider when phasing out a product and illustrates how a risk communication plan can be structured and implemented. How different stakeholders may be involved when a pesticide is going to be phased out is also described.
more
Access to safe, effective and quality-assured health products and technologies is crucial for achieving universal health coverage and primary health care goals. The continued growth of the aging population; increasing burden of noncommunicable diseases; growing burden of mental health issues; climat...e change; shifting patterns of vector borne diseases, fungal disease and waterborne diseases; antimicrobial resistance; and new infectious hazards create an ongoing need for equitable access to safe, effective and quality-assured health products and technologies, and renewed investments in research and development for innovative health products and technologies.
The coronavirus pandemic exposed the inequalities in access to health products, highlighting the need for longer-term strategies to strengthen access to health products and technologies outside of and in emergency situations. While technological and scientific advances present an opportunity to increase access to health products and technologies, the risk of increasing inequality due to higher prices for new health products and technologies; the persisting problem of substandard and falsified medical products; a lack of skilled workforce in many low- and middle-income countries; and a lack of data for decisionmaking and for measuring progress present significant challenges.
more
The 2024 edition reviews more than 50 health-related indicators from the Sustainable Development Goals and WHO’s Thirteenth General Programme of Work. It also highlights the findings from the Global health estimates 2021, notably the impact of the COVID-19 pandemic on life expectancy and healthy l...ife expectancy.
more
Exposure to air pollution has significant adverse health effects, leading to nearly 1 in every 8 deaths globally. Air pollution affects all age groups, from unborn children to older people, in both high- and low-income nations.
The MEDBOX Annual Report provides an overview of the most important projects of the past year
The objective of this guideline is to present the complete set of all WHO recommendations and best practice statements relating to abortion. While legal, regulatory, policy and service-delivery contexts may vary from country to country, the recommendations and best practices described in this docume...nt aim to enable evidence-based decision-making with respect to quality abortion care.
more
This publication provides an overview of evidence and guidance on the growing challenge of workplace heat stress in the context of climate change. It highlights the health and productivity risks faced by billions of workers, especially in manual labor sectors. The report details the physiological, s...ocioeconomic, and mental health impacts of heat stress and outlines evidence-based strategies for prevention and mitigation. It emphasizes the need for occupational heat action programmes, stakeholder collaboration, and tailored interventions to protect vulnerable workers, reduce productivity losses, and support sustainable development in a warming world.
more
Non-Communicable Diseases (NCDs) have emerged as conditions of great public health concern in Kenya accounting for 39% of deaths annually. The Ministry of Health through the Department of Non-Communicable Diseases has adopted the vision of achieving a nation free from preventable burden of NCDs. Fur...ther, the mission of this strategy is to halt and reverse the rising burden of NCDs through effective multisectoral collaboration and partnerships by ensuring Kenyans receive the highest attainable standard of NCD continuum of care that is accessible, affordable, quality, equitable and sustainable thus alleviating suffering, disease and death for their well-being and socio-economic development.
The scope of NCDs covered by this strategy include; cardiovascular diseases, cancer, diabetes, chronic respiratory diseases, mental health conditions, violence and injuries, hemoglobinopathies, haemophilia and other bleeding disorders, auto immune diseases, chronic renal diseases, epilepsy and other neurological disorders, chronic skin conditions and oral diseases and conditions. It equally addresses seven risk factors; tobacco use, harmful use of alcohol, unhealthy diets and toxins, physical inactivity, indoor air pollution, environmental pollutants and toxins and stress.
more
In the absence of a such a measure, and building on the success of developing the APCA African
Palliative Outcome Scale (POS) for adults, the African Palliative Care Association has developed the
APCA African Children’s POS. The tool has been validated across diseases, countries, settings and ...
languages and used in both quality improvement and research studies. Moreover, feedback on the
tool from doctors and nurses who have used it has been very supportive, with providers perceiving
it as an easy-to-use instrument that helps them undertake holistic assessments that in part entail
discussing difficult issues.
This booklet is a practical guide intended to help users employ the APCA African POS correctly.
Following a discussion of the origins and background to the APCA African PPOS, the guide discusses
the measurement of outcomes, the development of the tool and its use (including the analysis of
collected data), before finishing with illustrative examples of the use of the questionnaire.
more
In this guide, the African Palliative Care Association (APCA) has put together evidence‑based information on the use of specific opioids commonly used in the management of moderate‑to‑severe pain to manage both cancer and non‑cancer pain. APCA hopes that this guide will be a useful tool i...n aiding health professionals at all levels of healthcare delivery to assess and manage pain using opioids. All opioids included in this guide are listed on the WHO model list of essential medicines but we remind readers that oral morphine is the standard opioid of choice for managing moderate‑to‑severe pain and we recommend that it should be made available at all times.
more